Lexaria Bioscience Corp (CSE:LXX)(OTCMKTS:LXRP) has highlighted that its patented DehydraTECH technology-enabled CBD infused powders are now available for sale across the US, against the backdrop of consumer concern over cannabinoid potency.
DehydraTECH turns cannabis and hemp oils into stabilized powders, which allows for faster absorption into the human bloodstream.
The process also preserves the cannabinoids contained within and mitigates microbiological growth for longer shelf life, noted Lexaria on Thursday.
The firm sells its pre-processed CBD/hemp DehydraTECH powders directly to manufacturers for use within their own products.
In a statement, Lexaria cited a European study, which discovered that THC potency tends to degrade by over 20% per year, and CBD potency by over 10% per year.
It also noted that last year, two of North America's largest cannabis companies announced multi-million-dollar losses on aged cannabis inventories.
During the Fall last year, American farmers delivered the largest CBD/hemp crops in US history, leading to another glut of supply and plummeting prices for oils containing CBD, the firm added.
In addition, certain types of packaging, such as polystyrene, can also absorb between 60% and 100% of the THC within, if the consumer products have not been stabilized such as is possible with the DehydraTECH technology.
Contact the author at [email protected]